Brief: Gen Ilac Says Result Of Phase 1 Clinical Trials Of Sul-238 Indicates That It Is Safe And Well-Tolerated In Healthy Volunteers
28/07/2025 13:10
July 28 (Reuters) - Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS GENIL.IS: GEN ILAC- RESULT OF PHASE 1 CLINICAL TRIALS OF SUL-238 INDICATES THAT IT IS SAFE AND WELL-TOLERATED IN HEALTHY VOLUNTEERS GEN ILAC- RESULTS INDICATE SIGNIFICANT PROMISE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE Source text: ID:nIKAbK3s2C Further company coverage: GENIL.IS (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Gen Ilac ve Saglik Urunleri Sanayi Ticaret
See all newsBrief: Gen Ilac Says It Wins Pharmaceutical Tender In Kazakhstan, Expects $1.19 Million Sales Contribution In 2027
Brief: Gen Ilac Says It Participates In Kazakhstan Drug Procurement Tender Via Med Service Plus Authorized By Kazakhstan Representative Office Of Gen Ilac
Brief: Gen Ilac Says It Signs Supply And Distribution Agreement With Incyte On Oct 9
Brief: Gen Ilac Says It Completes Pharmaceutical Manufacturing Plant Investment In Azerbaijan
Brief: Gen Ilac Says It Is To Start Share Buyback Programme For Max 125 Mln Nominal Shares With Allocated Funds Of 1.5 Bln Lira